MAY 24, 2018 12:48 AM PDT

The Link Between Tuberculosis and Parkinson Disease

WRITTEN BY: Nouran Amin

There might be a link between Tuberculosis (TB) and Parkinson’s according to a study published in The EMBO Journal. This link is related to the mechanism behind how our immune system eradicates bacterial infections. More specifically, the study concluded that the mechanism is the same for Tuberculosis and Parkinson.

The findings, which will be published in The EMBO Journal, provide a possible explanation of the cause of Parkinson's disease and suggest that drugs designed to treat Parkinson's might work for TB too.

For Parkinson's disease, the most common genetic mutation occurs on the LRRK2, which allows the LRRK2 protein overactive. By examining the function of LRRK2 in immune cells known as macrophages that are infected with Mycobacterium tuberculosis (Mtb), the bacterium that leads to TB.

Using a combination of experimental approaches, Crick and GSK researchers, in collaboration with Matthias Trost, a proteomics specialist, from Newcastle University, discovered that LRRK2 inhibits phagosomes from fusing with lysosomes, decreasing their efficacy at clearing bacteria. Deletion of the LRRK2 gene or cell treatment using LRRK2 blockers might significantly reduce the levels of Mtb, treating TB. "We think that this mechanism might also be at play in Parkinson's disease, where abnormal masses of protein called 'Lewy bodies' build up in neurons in the brain and cause damage," explains Susanne Herbst, the first author of the study and post-doctoral fellow at the Crick.

Investigators suspect that LRRK2 might inhibit immune cells in the brain from degrading causing a build-up of protein in neurons that disrupts their neuronal function. "By studying TB, we have found a possible explanation for why LRRK2 mutations are a genetic risk factor for Parkinson's disease. It's exciting when different fields of research connect up in unexpected ways like this!" notes Susanne.

The findings also suggest that LRRK2 inhibitors could be a powerful new way for TB treatment. "LRRK2 inhibiting drugs are already being developed to treat Parkinson's disease and we're trying to see if we can repurpose them as a potential new TB therapy. This should be relatively straightforward because TB infects the lungs, so the LRRK2 inhibitors wouldn't need to cross the blood-brain barrier like they do in Parkinson's disease."

Sources: Crick

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 08, 2018
Immunology
AUG 08, 2018
Doxorubicin Causes Heart Toxicity by Immune System Disruption
Chemotherapy drug Doxorubicin disrupts metabolism that controls immune responses in the heart leading to heart toxicity....
AUG 28, 2018
Cell & Molecular Biology
AUG 28, 2018
Finding the Source of a Common Immune Cell
Neutrophils are a highly abundant type of immune cell, outnumbering every other kind that runs through the bloodstream....
SEP 22, 2018
Immunology
SEP 22, 2018
Could Diet Protect Against Brain Inflammation?
Immune brain cell inflammation due to aging can be mitigated through a high fiber diet...
OCT 21, 2018
Immunology
OCT 21, 2018
B -cells Drive auto-T-cells to the Brain
Researchers have provided a paradigm shift in the understanding of auto-reactive T cells in the brain of Multiple Sclerosis patients....
NOV 05, 2018
Immunology
NOV 05, 2018
Amino Acid Helps to Promote T cells
Scientists at Vanderbilt show that the amino acid glutamine can contribute to a subset of T cell function and activation...
DEC 04, 2018
Immunology
DEC 04, 2018
Natural HIV Resistance
A team of scientists discover unique immune reactions to the one percent of HIV infected patients that are able to fend off viral propagation without antiretroviral therapy...
Loading Comments...